MediciNova, Inc. (MNOV) Can’t Be More Safe. Trades Significantly Higher

February 15, 2018 - By Kurt Siggers

Investors sentiment increased to 2.67 in Q3 2017. Its up 1.21, from 1.46 in 2017Q2. It improved, as 2 investors sold MediciNova, Inc. shares while 7 reduced holdings. 4 funds opened positions while 20 raised stakes. 7.88 million shares or 0.85% more from 7.81 million shares in 2017Q2 were reported.
Credit Suisse Ag owns 25,949 shares. Voya Invest Management Ltd Liability holds 19,341 shares. Essex Woodlands Ventures Incorporated reported 1.17M shares or 1.32% of all its holdings. Deutsche Commercial Bank Ag reported 31,136 shares. Legal And General Grp Incorporated Public Ltd Company reported 0% in MediciNova, Inc. (NASDAQ:MNOV). D E Shaw And Company reported 0% stake. Moreover, Bridgeway Cap Mngmt Incorporated has 0.01% invested in MediciNova, Inc. (NASDAQ:MNOV) for 139,082 shares. Vanguard stated it has 0% of its portfolio in MediciNova, Inc. (NASDAQ:MNOV). Tower Research Capital Lc (Trc) reported 3,664 shares. State Street reported 0% stake. Massachusetts-based Fmr Ltd Liability has invested 0% in MediciNova, Inc. (NASDAQ:MNOV). Barclays Public Limited Com reported 1,188 shares stake. Schwab Charles Invest Mngmt reported 46,400 shares. State Of Wisconsin Investment Board holds 0% or 26,000 shares. Renaissance Limited Liability has invested 0% of its portfolio in MediciNova, Inc. (NASDAQ:MNOV).

The stock of MediciNova, Inc. (NASDAQ:MNOV) is a huge mover today! The stock increased 7.95% or $0.785 during the last trading session, reaching $10.655. About 278,031 shares traded or 39.03% up from the average. MediciNova, Inc. (NASDAQ:MNOV) has declined 6.61% since February 15, 2017 and is downtrending. It has underperformed by 23.31% the S&P500.
The move comes after 9 months positive chart setup for the $436.09 million company. It was reported on Feb, 15 by We have $11.61 PT which if reached, will make NASDAQ:MNOV worth $39.25M more.

More notable recent MediciNova, Inc. (NASDAQ:MNOV) news were published by: which released: “MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 …” on January 31, 2018, also with their article: “MediciNova to Present at the 98th Annual Meeting of the Chemical Society of Japan” published on January 16, 2018, published: “Here’s Why MediciNova, Inc. Stock Is Sliding Today” on February 08, 2018. More interesting news about MediciNova, Inc. (NASDAQ:MNOV) were released by: and their article: “MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in …” published on February 01, 2018 as well as‘s news article titled: “MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation …” with publication date: January 30, 2018.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company has market cap of $436.09 million. The companyÂ’s product candidate includes MN-166 , an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. It currently has negative earnings. The Company’s product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.